Document is current

Any future updates will be listed below

Correction to: SRRM2 may be a potential biomarker and immunotherapy target for multiple myeloma: a real-world study based on flow cytometry detection

Crossref DOI link: https://doi.org/10.1007/s10238-024-01393-1

Published Online: 2024-07-18

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark